Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug goes Head-to-Head with standard treatment for wet AMD

NCT ID NCT07816289

Disease control Sponsor: Ollin Biosciences, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing an experimental drug called OLN324 against ranibizumab, a standard treatment for wet age-related macular degeneration (nAMD). The trial enrolls about 400 adults aged 50 and older who have not yet received treatment for active wet AMD in the study eye. Participants receive monthly injections into the eye of either OLN324 or ranibizumab. The main goal is to compare changes in vision over 36 weeks, with additional checks on retinal thickness and other eye measurements.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OLN324, an experimental drug given as a monthly injection into the eye
What this could lead to
If OLN324 works as well as or better than ranibizumab, it could offer another treatment option for people with wet age-related macular degeneration.
What could go wrong
This is a Phase 3 trial, so OLN324 is still experimental. It may not match ranibizumab, and eye injections carry risks such as infection, bleeding, or increased eye pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Capable of giving signed informed consent * Be ≥50 years of age * Treatment-naive nAMD in the study eye with active subfoveal choroidal neovascularization (CNV) * Have a decrease in vision in the study eye due to nAMD, with best corrected visual acuity of 78 to 24 letters * Additional inclusion criteria apply Exclusion Criteria: * Be pregnant or breastfeeding * History of cataract surgery in the study eye within 90 days of Screening * Has uncontrolled glaucoma in the study eye * Has uncontrolled hypertension * Has had a stroke or myocardial infarction within 180 days * Additional exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Wet age related macular degeneration are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Wet age related macular degeneration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.